Issue 32, 2017

Hollow carbon nanospheres for targeted delivery of chemotherapeutics in breast cancer therapy

Abstract

We present novel hollow carbon nanospheres (HCNs) for targeted breast cancer therapy. The HCNs have a 40 nm-cavity for drugs loading, and the surface is covered with “natural” primary amine without any exogenous modification, equipped to conjugate with functional biomolecules. After modification with anti-HER2 antibody and loading of Doxorubicin (DOX) to the HCNs, the HER2@HCNs/DOX can specifically access HER2-positive breast cancer cells and significantly suppress the cells in vitro, causing ∼60% reduction of the volume of the HER2-positive tumours in vivo. The HCNs show great promise to become a multifunctional carrier in the field of high-loading capacity drug delivery for cancer therapy.

Graphical abstract: Hollow carbon nanospheres for targeted delivery of chemotherapeutics in breast cancer therapy

Supplementary files

Article information

Article type
Paper
Submitted
22 apr 2017
Accepted
17 may 2017
First published
17 may 2017

J. Mater. Chem. B, 2017,5, 6601-6607

Hollow carbon nanospheres for targeted delivery of chemotherapeutics in breast cancer therapy

L. Zhang, P. Wang, W. Zheng and X. Jiang, J. Mater. Chem. B, 2017, 5, 6601 DOI: 10.1039/C7TB01105A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements